Virginia Commonwealth University — Biomedical Watch V2

Essais liés32clinical trials

VilleRichmondlocalisation

PaysUnited Stateslocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05027269

Ouvrir le site du centre

Essais cliniques associés

Molécule	Indication / population	Phase	NCT	Titre	Statut
OPTIMIZER® Integra CCM-D System (Treatment Arm)	Maladie coronarienne	Non applicable	NCT05855135	INTEGRA-D — Assessment of Combined CCM and ICD Device in HFrEF	ACTIVE_NOT_RECRUITING
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL	Maladie coronarienne	Phase 3	NCT05739383	A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	ACTIVE_NOT_RECRUITING
XEN1101	Épilepsie	Phase 2	NCT03796962	X-TOLE — A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy	ACTIVE_NOT_RECRUITING
BMS-986504	Cancer	Phase 2/3	NCT07063745	MountainTAP-29 — A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion	RECRUITING
AFSW Guided DOAC	Accident vasculaire cérébral	Phase 3	NCT05836987	REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation	RECRUITING
AOC 1001	Myopathies	Phase 1/2	NCT05027269	MARINA — Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients	COMPLETED
Electrical Impedance Myography	Myopathies	À vérifier	NCT03458832	ReSolve — Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD	ACTIVE_NOT_RECRUITING
PsyMINT — mHealth Intervention for Pain Self Management	Alzheimer	Non applicable	NCT07332377	PsyMINT — mHealth Intervention for Pain Self Management	COMPLETED
Lab Assay for seven genetic variants for Parkinson's Disease	Parkinson	À vérifier	NCT04994015	Parkinson's Foundation PD GENEration Genetic Registry	RECRUITING
AOC 1001	Myopathies	Phase 2	NCT05479981	MARINA-OLE — Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients	COMPLETED
AOC 1001 (del-desiran)	Myopathies	Phase 3	NCT06411288	HARBOR — Global Study of Del-desiran for the Treatment of DM1	COMPLETED
GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy	Myopathies	À vérifier	NCT05257473	GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy	ACTIVE_NOT_RECRUITING
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)	Myopathies	À vérifier	NCT03981575	Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)	RECRUITING
ASPIRE-DM1 — DMCRN-02-001: Assessing Pediatric Endpoints in DM1	Myopathies	À vérifier	NCT05224778	ASPIRE-DM1 — DMCRN-02-001: Assessing Pediatric Endpoints in DM1	RECRUITING
Atogepant	Migraine	Phase 3	NCT03777059	12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine	COMPLETED
CNP-106	Myasthénie	Phase 1/2	NCT06106672	Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis	ACTIVE_NOT_RECRUITING
AOC 1020	Myopathies	Phase 2	NCT06547216	FORTITUDE-OLE — Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)	ACTIVE_NOT_RECRUITING
AOC 1020	Myopathies	Phase 1/2	NCT05747924	FORTITUDE — Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)	COMPLETED
Iptacopan (part 1)	Lupus	Phase 2	NCT05268289	Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V	TERMINATED
Acoramidis	Alzheimer	Phase 3	NCT06563895	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	RECRUITING
bemdaneprocel	Parkinson	Phase 3	NCT06944522	exPDite-2 — A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease	RECRUITING
ASSESS ALL ALS Study	Sclérose latérale amyotrophique	À vérifier	NCT06578195	ASSESS ALL ALS Study	RECRUITING
PREVENT ALL ALS Study	Sclérose latérale amyotrophique	À vérifier	NCT06581861	PREVENT ALL ALS Study	RECRUITING
BBP-418	Myopathies	Phase 2	NCT04800874	Study of BBP-418 in Patients With LGMD2I	ACTIVE_NOT_RECRUITING
Del-desiran (AOC 1001)	Myopathies	Phase 3	NCT07008469	HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1	ENROLLING_BY_INVITATION
AOC-1020	Myopathies	Phase 3	NCT07038200	FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD	RECRUITING
END-EXT — Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension	Myopathies	À vérifier	NCT07700225	END-EXT — Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension	RECRUITING
TREAT-EXT — Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension	Myopathies	À vérifier	NCT06747884	TREAT-EXT — Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension	RECRUITING
DYNE-251	Myopathies	Phase 1/2	NCT05524883	DELIVER — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping	ACTIVE_NOT_RECRUITING
Remibrutinib oral treatment	SEP	Phase 3	NCT06846281	Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	RECRUITING
Early Highly Effective Therapies Group	SEP	Phase 4	NCT03535298	DELIVER-MS — Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS	ACTIVE_NOT_RECRUITING
Descartes-08	Myasthénie	Phase 2	NCT04146051	Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)	ACTIVE_NOT_RECRUITING